Chronic urticaria sera increase basophil CD203c expression

Yasnowsky, K.M.; Dreskin, Stephen C.; Efaw, Benjamin; Schoen, David J.; Vedanthan, P.K.; Alam, Rafeul; Harbeck, Ronald J.

doi:10.1016/j.jaci.2006.02.016

Cited by 102 publications

(87 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior reports with basophil activation test (BAT; consisting of sera of CSU patients incubated with resting basophils of normal donors) induce histamine release and upregulate CD63 and CD203c (22,23). BAT with CD63 may have a role in assessing severity of disease and predicting outcome, but results are not completely homogeneous.…”

Section: Figure 2 -Disease Severity Variations After 12 Months Of Symmentioning

confidence: 99%

Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Berti

Yacoub

Skov

et al. 2017

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

show abstract

Section: Figure 2 -Disease Severity Variations After 12 Months Of Symmentioning

confidence: 99%

Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Berti

Yacoub

Skov

et al. 2017

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

show abstract

“…An increasing number of studies has confirmed the usefulness of BAT with donor basophils in the diagnosis and pathogenetic elucidation of chronic urticaria [129,130,131,132,133,134,135,136,137,138]. …”

Section: Clinical Indications Of Batmentioning

confidence: 99%

Diagnostic Tests Based on Human Basophils: More Potentials and Perspectives than Pitfalls

Weck

Sánz

Gamboa

et al. 2008

Int Arch Allergy Immunol

171

178

View full text Add to dashboard Cite

For the diagnosis of allergy, cellular basophil activation tests (BAT), e.g. histamine or sulfidoleukotriene release tests, have long been introduced, but the expression of basophil activation markers such as CD63 and CD203c detected by flow cytometry has attracted more recent attention. A recent opinion paper in this Journal has stressed not only the potential but also the possible pitfalls of flow-cytometric BAT. We have applied clinical validation of various BAT in various ways for several years, and our experience shows that these new technologies have more potentials and perspectives than pitfalls. A comprehensive review of clinically validated studies on allergy to aeroallergens, insect venoms, latex, food allergens and drugs, e.g. myorelaxants, β-lactams, pyrazolones and non-steroidal anti-inflammatory drugs, as well as chronic urticaria shows clearly that even with different protocols, reproducible and meaningful results can be obtained. Although the available technologies may still be optimized and better standardized, there are no serious reasons to deprive allergic patients of clinically indicated BAT, which can be performed reliably by any laboratory with allergy and flow-cytometric capacity and expertise.

show abstract

“…After ROC curve analysis, we concluded that CD203c did not have sufficient diagnostic power. Other authors, who tested CD63 [11][12][13][14][15] or CD203c expression [17] in CU patients, found significant correlation between ASST and both basophil activation tests positivity. The discrepancy between CD63 and CD203c correlations with ASST in our study can reflect either different mechanism of CD63 and CD203c molecules upregulation or differences in methodology of tests.…”

Section: Discussionmentioning

confidence: 92%

“…Recently, the ability of CU patient's serum to evoke expression of CD63 and CD203c on donor human basophils assessed by flow cytometry has been tested. There are a few published studies assessing serum-induced CD63 expression measurement as a diagnostic tool in CAU [11][12][13][14][15][16] and only 2 studies done by measured CD203c expression [16,17].…”

Section: Introductionmentioning

confidence: 99%